single-injection once-monthly antibody delivered subcutaneously for the treatment of Alzheimer's disease that targets a key epitope at the N-terminus of amyloid beta (Aß) with high binding potency.

The availability of amyloid-reducing therapies now makes detection of Alzheimer's disease in its early stages critical, ...

Alzheimer disease (AD) is the sixth leading cause of death in the United States and is projected to affect over 13 million ...

The results were presented at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) Conference. The DMN is responsible for ...

Acumen, with a strong cash position of $258.9 million, is poised to sustain operations into 2027, boosting investor confidence in their innovative approach to targeting toxic amyloid beta oligomers in ...

The positive rate of amyloid beta protein, indicating the risk of Alzheimer's disease-causing substance accumulation, was ...

With our clinical program gaining momentum and sabirnetug’s unique selectivity for toxic amyloid beta oligomers, we are excited about the potential to offer a next-generation treatment for early ...

Dr Charles Vega believes that primary care will be the chief clinical setting for application of new blood-based biomarkers.

and they work by taking out amyloid beta from the brain. Amyloid is part of what causes Alzheimer's disease. Now, what we're ...

New research offers hope for delaying Alzheimer’s disease progression by years after initial diagnosis. Alzheimer’s disease is a leading cause of death among those aged 65 or older. As the most common ...

Panax ginseng shows highest effectiveness in treating Alzheimer's. Learn more about AVXL's blarcamesine and SAVA's simufilam ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...